Astellas Pharma

Astellas Pharma OCF Margin

The Operating Cash Flow Margin of Astellas Pharma (4503.T) as of Oct 30, 2026 is 26.47 %. In the previous year, Operating Cash Flow Margin was 10.54 % — a change of 151.07% (higher).

OCF Margin

26.47 %

YoY

151.07%

Last updated:

Operating Cash Flow Margin of Astellas Pharma is 2026 26.47 % . Operating Cash Flow Margin of Astellas Pharma was 2025 10.54 % . It decreases by 151.07% higher compared to the previous year.

The Astellas Pharma OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2019
20.01 JPY
Jan 1, 2020
17.07 JPY
Jan 1, 2021
24.56 JPY
Jan 1, 2022
19.86 JPY
Jan 1, 2023
21.58 JPY
Jan 1, 2024
11.31 JPY
Jan 1, 2025
10.54 JPY
Jan 1, 2026
26.47 JPY
The Astellas Pharma OCF Margin history
YEAROCF MarginYoY
26.47 %+151.07%
10.54 %-6.76%
11.31 %-47.61%
21.58 %+8.67%
19.86 %-19.12%
24.56 %+43.90%
17.07 %-14.72%
20.01 %-17.25%
24.18 %+33.71%
18.09 %-21.57%
23.06 %+51.39%
15.23 %-20.20%
19.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Astellas Pharma Stock analysis

What does Astellas Pharma do? Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Astellas Pharma stock

Operating Cash Flow Margin of Astellas Pharma is 26.47 % in 2026.

Operating Cash Flow Margin of Astellas Pharma changed from 10.54 % to 26.47 %, representing a 151.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Astellas Pharma since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Astellas Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Astellas Pharma

All Key Metrics — Astellas Pharma